Lupin gets USFDA nod to market its skin conditions cream
New Delhi: Drug firm Lupin said it has received the final nod from the US health regulator to market its Clobetasol Propionate cream used for the treatment of various skin conditions.
The company has received final approval to market its generic Clobetasol Propionate cream USP, 0.05 percent, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
The company's product is a generic version of Fougera Pharmaceuticals Inc's Temovate cream, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd